Viracta Therapeutics to Present at the Jefferies Virtual Healthcare Conference
News provided by
Share this article
SAN DIEGO, May 27, 2021 /PRNewswire/
Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021. The Company will also participate in one-on-one investor meetings at the conference.
Details on the presentation can be found below.
Date:
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta s proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associat
BOSTON, 27. Mai 2021 PRNewswire/ Visionairy Health (VH), ein KI-Unternehmen im Gesundheitsbereich, gab heute bekannt, dass es die CE-Kennzeichnung für X1.
Item 9 Labs, Vertically Integrated Cannabis Operator and Leading Dispensary Franchisor, to Present at Two Virtual Investor Conferences in June 2021
-Benzinga Cannabis Capital Conference takes place June 3-4
- LD Micro Main Event Conference takes place June 8-10
- Company recently reported 6th consecutive quarter of revenue growth, achieving profitability for Second Quarter Fiscal Year 2021
News provided by
Share this article
Share this article
PHOENIX, May 27, 2021 /PRNewswire/ Item 9 Labs Corp. (OTCQX: INLB) ( Item 9 Labs or the Company ), a vertically integrated cannabis operator that produces premium, award-winning products and dispensary franchisor, today announced speaking engagements at two virtual investor conferences being held in June 2021.